1993 Fiscal Year Final Research Report Summary
Identification of HTLV-1 neutralizing epitopes and the development of an HTLV-1 peptide based vaccine
| Project/Area Number |
04670391
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
内科学一般
|
|---|
| Research Institution | Kyushu University |
|---|
Principal Investigator |
NAKAMURA Minoru Kyushu University, Faculty of Medicine, Research Associte, 医学部, 助手 (40217906)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAKANO Shuji Kyushu University, Faculty of Medicine, Research Associte, 医学部, 助手 (40164248)
|
|---|
| Project Period (FY) |
1992 – 1993
|
| Keywords | B lymphocyte repertoire / human monoclonal antibody / anti-HTLV-1 antibody / neutralizing epitope / peptide based vaccine / B cell epitope / T cell epitope / anti-mitochondrial antibody |
|---|
| Research Abstract |
We have generated a number of human monoclonal antibodies(mAb) to HTLV-1 by transforming B lymphocyte with EBV.Peripheral blood obtained from patients with HAM/TSP was used as a source of B lymphocytes committed to the production of IgG antibodies to HTLV-1. By using these mAb, we have identified the principle linear neutralizing B cell epitopes of HTLV-1 on the envelope protein gp46 a.a.187-199. Thus, we proposed that this region would be a good candidate for a peptide based HTLV-1 vaccine. In order to develop a peptide based vaccine which can induce a high titer of neutralizing antibodies against HTLV-1, we first synthesized peptides of various lengths containing an a.a.sequence of the principle neutralizing determinant of HTLV-1 gp46 a.a.187-199. Then, we conjugated these peptides with MAP.High titers of neutralizing antibodies were induced by immunization of MAP181-210 in various strains of rats and rabbits. We also identified the major T cell epitope on gp46 a.a.194-210 in various strains of rats Furthermore, MAP181-210 contains a T cell helper epitope on a.a.194-210 in humans with various HLA haplotypes. It is therefore possible that MAP181-210 could become one of the first candidates of a peptide based vaccine for human use.
|
